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Summary Although Hodgkin lymphoma (HL) is consid-
ered one of the most curable human cancers, the treatment
of patients with relapsed and refractory disease, especially
those who relapse after autologous stem cell transplanta-
tion, remains challenging. Furthermore, because of the
young age of these patients, the impact of early mortality on
the number of years lost from productive life is remarkable.
Patients with relapsed HL post stem cell transplantation
currently have no curative therapy, and are in need for new
drugs and novel treatment strategies. While no new drugs
have been approved for the treatment of patients with HL in
more than three decades, several new agents are demon-
strating promising results in early clinical trials. This review
will focus on the emerging role of histone deacetylase
inhibitors in patients with relapsed HL.
Keywords Hodgkin lymphoma.Role of histone
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Introduction
Epigenetics is a heritable process that alters gene expression
without changing the DNA sequence [1]. This process
includes DNA and chromatin modifications by methylation,
acetylation, phosphorylation, ubiquitylation, and sumolya-
tion. Epigenetic processes are natural and essential to many
organism functions, but if they occur improperly, they may
result in major adverse health effects. The best known
epigenetic process is DNA methylation, which involves the
addition of a methyl group (CH3), which primarily occurs at
the 5′ position of the pyrimidine ring of the cytosine. The
resulting methylcytosine is mainly found in cytosine-guanine
(CpG) islands [2]. The presence of 5-methylcytosine in the
promoter of specific genes alters the binding of transcrip-
tional factors and other proteins to DNA and recruits methyl-
DNA-binding proteins and histone deacetylases that compact
the chromatin around the gene-transcription start site. Both
mechanisms block transcription and cause gene silencing.
Another significant epigenetic process is the post-
transcriptional modification of histones. Chromatin is the
complex of histone proteins and DNA that is tightly bundled
to fit into the nucleus. The complex can be modified by
histone acetylation, which alters chromatin structure to
influence gene expression [3]. In general, tightly folded
chromatin tends to be shut down, or not expressed, while
more open chromatin is functional, or expressed. Among all
theepigeneticresearchconducted sofar,themost extensively
studied disease family is cancer, and the evidence linking
epigenetic processes with cancer continues to grow [1, 4, 5].
Histone deacetylases (HDACs)
Post-transcriptional histone modification plays an important
role in regulating gene transcription, and is mediated by a
variety of enzymes, including histone acetyltransferases
(HATs) and histone deacetylation (HDACs) [3]. These
enzymes mediate acetylation and deacetylation of specific
lysine amino acid residues on histone tails. In general,
histone H3 and H4 acetylation is associated with open
chromatin status favoring gene transcription, whereas
histone deacetylation is associated with closed chromatin
status favoring transcription repression and gene silencing.
The balance between HATs and HDACs is critical for
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involved in cell proliferation, survival, angiogenesis, and
immunity [6–8]. To date, 18 HDACs have been identified
in humans [9, 10]. HDACs are grouped in two major
categories: zinc-dependent HDACs and NAD-dependent
HDACs. Furthermore, HDACs are classified into four
major classes: Class I includes HDAC 1, 2, 3, 8, and 11;
Class II includes HDAC 4, 5, 6, 7, 9, and 10; Class III
includes homologues of yeast SIRT 1–7, and Class IV,
which currently includes only HDAC 11 (Fig. 1). Class III
is NAD-dependent, whereas classes I, II, and IV are zinc
dependent. In addition to histones, HATs mediate post-
translational protein acetylation on lysine residues in a
variety of nonhistone proteins, including transcription
factors (p53, STAT3, MYC, GATA-1, GATA-2, E2F, NF-
κB, nuclear receptors, HIF-1α, and TEL), α-tubulin, and
heat shock protein-90 (HSP90) [3, 11–13].
HDAC inhibitors (HDACis)
Because HDACs target histones and a variety of nonhistone
proteins that control cell survival, proliferation, angiogen-
esis, and immunity, they became attractive targets for
cancer therapy. At the present time, clinical grade pharma-
cologic inhibitors of the zinc-dependent HDACs are
available for clinical trials, and two inhibitors, vorinostat
and romidepsin, have already been approved by the FDA
for the treatment of patients with relapsed cutaneous T-cell
lymphoma [14, 15]. Vorinostat inhibits a wide range of
HDACs, including classes I and II, and therefore is
frequently referred to as pan-DAC inhibitor. Although
Romidepsin is considered a pan-DAC inhibitor as well, it
shows stronger activity against class I than against the class
II HDACs [9]. In contrast, entinostat (SNDX-275) and
mocetinostat (MGCD0103) are selective inhibitors that
preferentially inhibit class I HDACs and to a less extent
class IV (Fig. 2)[ 16].
HDACis mediate antitumor activity by modulating a
variety of survival pathways [3, 9, 13, 17]. HDACis induce
cell cycle arrest by regulating the expression of p21 and
p27 cell-cycle proteins, in addition to inducing cell death by
activating the intrinsic and extrinsic apoptosis pathways. In
fact, a variety of HDACi have been shown to transcrip-
tionally regulate several components of the death pathways,
including upregulation of proapoptotic proteins (Bak, Bax,
Apaf-1, Bad, Bim, Bid, caspase3, and 9), and repression of
antiapoptotic proteins (Bcl2, Bcl-xL, Mcl-1, XIAP, cFLIP).
Furthermore, HDACi have been reported to upregulate the
transcription of TRAIL and its death receptors and Fas
ligand (C95L) and Fas [18–20].
Several HDACis are currently being evaluated for the
treatment of cancer, and there is accumulating evidence that
this treatment strategy is effective for the treatment of
hematologic malignancies in general, and lymphoid malignan-
cies in particular [13, 19, 21, 22]. In fact, several HDACis
have recently reported promising clinical activity, including
clinical remissions, in patients with Hodgkin lymphoma (HL)
and non-Hodgkin lymphoma (NHL) [23–29].
Fig. 1 Zinc-dependent HDACs
Fig. 2 A schematic grouping of HDAC inhibitors and their
mechanisms of action
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HRS cells are B cells with epigentically-silenced B-cell
genes Molecular analysis demonstrated that the malignant
Hodgkin and Reed-Sternberg (HRS) cells of Hodgkin
lymphoma (HL) are of B-cell origin. However, HRS cells
infrequently express B-cell antigens. This loss of B-cell
phenotype has been reported to be epigenetically regulated
and is thought to enable HRS cells to evade immunosur-
veillance. For example, gene expression profiles of HRS
cells revealed decreased mRNA levels for nearly all B-cell
lineage-specific genes [30]. The decrease in mRNA
expression was associated with downregulation of protein
expression in primary HL cases, as determined by immu-
nohistochemistry, including CD20, CD19, Syk, Lck, Blk,
Oct-2, and B-cell receptor [30]. Furthermore, microdis-
sected primary HRS cells and HL cell lines are down-
regulated in HL. Importantly, the expression of these
silenced genes could be re-induced by the DNA hypome-
thylating agent 5-aza-deoxycytidine [31, 32]. A variety of
HDAC inhibitors have demonstrated promising pre-clinical
activity in HL cell lines by inducing cell cycle arrest and
apoptosis [28]. AT the molecular level, HDACis upregu-
lated p21, activated the caspase pathway, downregulated
STAT6 expression, and altered cytokine and chemokine
secretion [33–35]. In fact, we have recently demonstrated
that vorinostat decreased the expression and secretion of
Th2-type cytokines and chemokines, including Thymus and
Activation-Regulated Chemokine (TARC/CCL17) and in-
terleukin (IL)-5, and increased Th1-type cytokines/chemo-
kines, including a profound increase in IP-10 levels,
suggesting that HDACi may alter the microenvironment
surrounding HRS cells to favor cell death [35].
Epigenetic therapy induces the expression of Epstein-Barr
virus antigens and tumor-associated antigens in HRS cells,
which are potential targets for cytotoxic T cells Epstein-
Barr virus (EBV)-associated antigens are known to be
expressed by a proportion of HRS cells, however, only the
subdominant EBVantigens LMP1 and LMP2 are expressed
and provide T-cell target antigens. EBV-specific T cells that
are enriched for LMP-specific T-cell clones have been
expanded from patients and administered to patients with
relapsed disease [36, 37]. Unfortunately, T cells specific for
the viral latent nuclear antigens, EBNAs 3A, 3B and 3 C
and the immediate early lytic cycle antigen, BZLF1,
BRLF1 and BMLF1 dominate the human immune response
to EBV. If these proteins could be reactivated in EBV-
positive HRS cells, then their susceptibility to EBV-specific
T-cell lines would be increased. Both HDACis and
hypomethylating agents induce EBV gene expression.
HDACs reactivate EBV from latency to replication, so that
the immunogenic lytic cycle antigens are expressed [38–
40], while azacytidine can switch latently infected cells
from a minimal form of latency (LMP1,LMP2 and
EBNA1) to an unrestricted latency in which all EBNAs
(2, 3’s and-LP) and LMPs are expressed. Thus, these drugs
may transform poorly antigenic tumors into highly immu-
nogenic tumors and increase the number of available target
antigens for T-cell recognition immunodominant viral
proteins. In addition, combining different agents like
chemotherapy and HDAC inhibitors results in synergistic
effects on activating lytic viral replication [40]. Since only
about 20% of patients with relapsed HL have EBV-positive
tumors, it is also important to determine if other tumor-
associated, T-cell target antigens are upregulated by
epigenetic therapy. Cancer Testis Antigens (CTAs) are
known to comprise at least 44 families of genes or
isoforms. Among these, 19 families are purely testis-
restricted, while others are expressed in one or more
somatic tissues. Some CTAs are expressed in lymphoma
[41, 42], and provide potential T-cell targets. CTA-specific
T cells from melanoma patients have demonstrated thera-
peutic benefits, including complete remissions. CTA-
specific CTL could have similar beneficial effects in
EBV-negative lymphomas. Recently, hypomethylating
agents have been shown to induce the expression of several
CTAs in cultured tumor cell lines (including lymphomas)
[43]. Such upregulated expression has been reported for
several MAGE members – LAGE-1, SSX-2, CAGE, and
NY-ESO-1. Demethylation proved necessary and sufficient
for MAGE-A1 gene expression in melanoma cell lines,
suggesting that methylation is a primary mechanism of
transcription control. Histone deacetylase (HDAC) inhib-
itors, on their own, or in combination with hypomethylating
agents, can also induce CTA expression, including MAGE,
SSX, and NY-ESO-1 family members [43]. Recent data
suggested that HDACi may upregulate the expression of
CTA in HRS, suggesting HDACis may enhance the activity
of EBV-directed cellular therapy in HL [33]. Since
epigenetically enhanced CTA expression may activate
endogenous CTA-specific T cells in vivo, this may induce
epitope spreading and facilitate the ex vivo activation and
expansion of these normally low frequency CTA-specific T
cells.
Clinical results with HDACi in patients with HL
A variety of HDACis are currently being evaluated in
patients with relapsed HL (Table 1). The following is a
brief update on the current status of HDACis in patients
with relapsed HL. Interestingly, the expression pattern of
HDAC enzymes varied among different types of lymphoma
[44]. Consistent with their ubiquitous distribution in normal
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Hodgkin and non-Hodgkin lymphoma cell lines and
primary tumors studied, including the non-malignant
reactive cells in HL microenvironment. In contrast, the
class II enzyme HDAC6 was infrequently expressed,
compared with HDACs 5, 8, and 10. These results suggest
that HDAC6 may not be an important therapeutic target in
selected lymphoid malignancies [44].
Vorinostat (SAHA) Vorinostat, which inhibits HDAC clas-
ses I and II, has a potent antiproliferative activity in HL cell
lines, as it induces cell cycle arrest and apoptosis, in
addition to synergizing with chemotherapy [45]. Furthe-
more, Vorinostat inhibited STAT6 phosphorylation and
transcription in HL cell lines, an effect that was associated
w i t hd e c r e a s e de x p r e s s i o na n ds e c r e t i o no fT h 2 - t y p e
cytokines and chemokines (TARC and IL-5). This effect
was associated with and increases of in Th1-type cytokines/
chemokines (IP-10) [45]. The in vivo activity of vorinostat
was recently evaluated in a phase II study that was
conducted by the Southwest Oncology Group (SWOG) in
patients with relapsed HL [16]. Twenty-five patients were
treated with 200 mg vorinostat given orally twice per day
for 14 days every 21-day cycle. Vorinostat produced
modest clinical activity, as only 1 patient (4%) achieved a
partial remission.
Mocetinostat (MGCD-0103) Mecetinostat is a novel oral
HDAC inhibitor that selectively inhibits HDAC 1, 2, 3
(class I) and 11 (class IV) isoforms, with no effect on class-
II HDACs [46]. The safety and efficacy of MGCD-0103
given orally 3 times per week (85 to 110 mg starting doses)
has been evaluated in a phase II study in patients with
relapsed and refractory HL [26]. Patients were allowed to
continue therapy up to 1 year in absence of heavy toxicity
or disease progression. Of the 20 patients who were treated
with 110-mg dose level, 7 (35%) patients achieved partial
or complete remissions. However, this dose level was
poorly tolerated resulting in dose interruptions and reduc-
tions, and discontinuation of therapy after a median of
4.5 months. Subsequently, the study was revised to allow a
lower starting dose of 85 mg at the same schedule. Three of
the 10 (30%) patients enro l l e do nt h er e d u c e dd o s e
achieved partial remissions. Furthermore, grade 3 and 4
toxicity (mainly fatigue, with no significant hematologic
toxicity) was reduced to 20%. Overall, 80% of the 30
evaluable patients had some decrease in their tumor
measurements. Although none of the patients developed
significant EKG abnormalities, two patients developed
significant pericardial effusions requiring discontinuation
of therapy [47]. Importantly, Serum TARC levels were
determined in 15 patients before and 1 week after initiation
of therapy [26]. After 1 week of therapy serum TARC
levels were decreased by at least 40% in five patients, and
all achieved major clinical responses. Collectively, this data
indicate that class I HDAC inhibitors have a potential
therapeutic value in patients with HL.
Panobinostat (LBH 589) Panobinostat is one of the most
potent HDACis in HL in vitro, with an IC50 in the
nanomolar range [28]. Recently panobinostat was evaluated
in a phase I trial in patients with hematologic malignancies
that also included patients with relapsed HL [18]. Five of
13 (38%) patients achieved partial remissions. The most
common side effects were fatigue, thrombocytopenia,
nausea, and diarrhea. Based on this promising clinical
activity, a large international phase II study of panobinostat
in relapsed HL, with an early report demonstrating a
promising clinical activity in a large multicenter settings
[48]. In a most recent update of the study, 61 patients have
been enrolled and treated: median age 31 years (range 18–
70), and 48% had stage III/IV at initial diagnosis. Patients
were heavily pretreated with a median number of prior
regimens of 4 (range 2–6 regimens). Of 61 patients, 53
have completed two cycles of therapy and have had one
post baseline imaging studies to evaluate response to
theapy. Sixty-nine percent had tumor reduction, including
one complete response and 10 partial responses The most
common grade 3/4 adverse events were thrombocytopenia
(77%), anemia (20%), and neutropenia (16%). Thrombo-
cytopenia was reversible within an average of 1 week of
dose interruption. No cases of grade 3/4 QTc prolongation
have been reported. Thus, panobinostat has a promising
clinical activity with a good safety profile. Based on this
promising data, panobinostat-based combination studies are
currently being conducted, including a phase I/II trial of
Table 1 Summary results of HDACi in patients with relapsed cHL
Drug Target Route Phase Number of evaluable patients PR CR PR + CR (ORR)
MGCD0103 [26] HDACs Oral II 21 6 2 8 (38%)
ITF2357 [49] HDACs Oral II 13 0 0 0
Panobinostat [51] HDACs Oral I 20 8 0 8 (40%)
Panobinostat [48] HDACs Oral II 53 10 1 11 (21%)
Vorinostat [24] HDACs Oral II 25 1 0 1 (4%)
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and non-Hodgkin lymphoma.
Entinostat (SNDX-275) Entinostat is an oral, class I iso-
form selective HDAC inhibitor. Phase 1 studies in leukemia
demonstrated the agent has a long half-life and that weekly
or every other week dosing is sufficient for antitumor
activity. In vitro experiments demonstrated a potent activity
of entinostat in HL-derived cell lines, with an IC50 of
0.4 μM[ 33]. At the molecular level, entinostat induced its
antiproliferative effect in HL cell lines by multiple
mechanisms: it increased H3 acetylation, up-regulated p21
protein expression, and activated the intrinsic apoptosis
pathway by down-regulating the anti-apoptotic X-linked
inhibitor or apoptosis (XIAP) protein, which was associated
with activation of caspase 9 and 3 [33]. Furthermore,
entinostat had synergistic effects when combined with
gemcitabine and bortezomib. Moreover, entinostat increased
IL12 p40-70, IP10, and RANTES, and decreased the level of
IL13 and IL4, in HL cell lines supernatants, thus favoring
Th1-type cytokines/chemokines. Finally, entinostat induced
the expression of a variety of tumor-associated antigens,
including SSX2 and MAGE-A [33]. Based on this encour-
aging in vitro data, the safety and efficacy of entinostat is
currently being evaluated in a phase 2 multi-center study in
patient with relapsed or refractory HL. In this study
entinostat is given 10 mg (two 5 mg tablets) orally, once
every two weeks (days 1 and 15) in a 28 day cycle
increasing to 15 mg in absence of treatment related toxicity.
Results of this study are expected to be available in 2010.
ITF 2357 ITF 2357 is a selective class I and class II HDAC
inhibitor. The efficacy, safety, and tolerability of daily 100-
mg doses of ITF 2357 in relapsed/refractory HL were
investigated in a phase II clinical trial at the National
Tumors Institute of Milan [49]. The preliminary results
were presented at the 2008 ASCO meeting: 15 patients
were enrolled and 13 were evaluable for response. Seven
patients (54%) had a stable disease, with a reduction in
FDG-PET uptake in six patients (46%) lasting at least
3 months; six patients had disease progression. Interesting-
ly, a correlation was found between a decrease in serum
TARC levels and the response to treatment in this study. On
the basis of the single-agent activity of ITF 2357 and the
documented synergistic activity of ITF 2357 and mechlor-
ethamine in HL cell lines, a phase II trial of ITF 2357
combined with mechlorethamine was conducted by the
same group [50]. Nineteen patients who unsuccessfully
underwent prior autologous/allogeneic stem cell transplan-
tation were enrolled. Preliminary data from 17 evaluable
patients demonstrated that two patients (12%) achieved
complete and three (18%) partial remissions. As expected,
the major toxicity was hematologic, with seven patients
experiencing grade III/IV neutropenia and eight having
thrombocytopenia;fourpatients experiencedinfectionsduring
treatment.Takentogether,thesedatasuggestthatITF2357has
encouraging clinical activity in relapsed/refractory HL.
Conclusions
Class I and pan-DAC inhibitors are promising new agents
for the treatment of patients with relapsed HL. Future
studies should examine predictive biomarkers, such as
TARC levels and the pattern of HDAC enzyme expression
in HL patients treated with HDACis to determine whether a
certain pattern of expression may predict response to
therapy. Furthermore, because HDAC inhibitors can mod-
ulate a variety of survival proteins, combination regimens
with HDAC inhibitors should be investigated. Ultimately,
these studies will hopefully improve our treatment strate-
gies for patients with relapsed and refractory HL.
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